A pivotal trial of pamiparib (BGB-290), an investigational PARP inhibitor, in Chinese patients with advanced ovarian cancer
Phase of Trial: Phase II
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Pamiparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 18 Dec 2017 According to a BeiGene media release, the first patient has been dosed in this trial. Professor Xiaohua Wu of the Fudan University Cancer Center is the lead principal investigator of the trial.
- 18 Dec 2017 Status changed from planning to recruiting according to a BeiGene media release.
- 22 Nov 2017 New trial record